---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-014876"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2024-04-04T23:59:59+00:00"
generated_at: "2026-06-04T02:15:23.380401+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Aadi Bioscience amends FYARRO supply agreement with Fresenius Kabi, extends term to July 31, 2024

## Summary
- Amendment effective March 31, 2024 extends supply agreement for FYARRO through July 31, 2024 (or later agreed date).
- Revised pricing, forecasting, compliance terms, and minimum purchase obligations for FYARRO from Fresenius Kabi.
- Contains other customary terms for biotech manufacturing; full amendment to be filed in subsequent periodic report.

## SEC filing metadata
- accession: 0001628280-24-014876
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2024-04-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000162828024014876/0001628280-24-014876-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000162828024014876/aadi-20240401.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-014876
- JSON: https://secwatch.observer/filing/0001628280-24-014876.json
- Plain text: https://secwatch.observer/filing/0001628280-24-014876.txt

## Key facts
- Material Agreements
  Whitehawk Therapeutics, Inc. amended Amendment No.2 (the "Amendment") to the Negotiated Purchase Order Terms and Conditions for Clinical and Commercial Product (the "Agreement") with Fresenius Kabi, LLC (effective 2024-03-31).
  - Action: amendment
  - Agreement: supply
  - Counterparty: Fresenius Kabi, LLC
  - Effective: 2024-03-31
  source text: On April 1, 2024, Aadi Bioscience, Inc. (the “Company”) entered into Amendment No.2 (the “Amendment”) to the Negotiated Purchase Order Terms and Conditions for Clinical and Commercial Product (the “Agreement”) with Fresenius Kabi, LLC (“Fresenius Kabi”). The Amendment is effective as of March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000162828024014876/0001628280-24-014876-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.